Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer

References

• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin201363113023335087
   PubMed Web of Science ®Google Scholar
• HotteSJSaadFCurrent management of castrate-resistant prostate cancerCurr Oncol201017 Suppl 2S72S7920882137
   PubMed Web of Science ®Google Scholar
• ScherHIHalabiSTannockIDesign and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupJ Clin Oncol2008261148115918309951
   PubMed Web of Science ®Google Scholar
• ChengHHAdvanced Clinical States in Prostate CancerKibelASUrologic Clinics of North America2012
   Google Scholar
• HeidenreichASchraderAJThe treatment of hormone refractory prostate cancerEAU Update Series200314050
   Google Scholar
• PetrylakDPThe treatment of hormone-refractory prostate cancer: docetaxel and beyondRev Urol20068 Suppl 2S48S5517021642
   PubMedGoogle Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med20043511513152015470214
   PubMed Web of Science ®Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med20043511502151215470213
   PubMed Web of Science ®Google Scholar
• ScherHIFizaziKSaadFIncreased survival with enzalutamide in prostate cancer after chemotherapyN Engl J Med20123671187119722894553
   PubMed Web of Science ®Google Scholar
• RyanCJSmithMRde BonoJSAbiraterone in metastatic prostate cancer without previous chemotherapyN Engl J Med201336813814823228172
   PubMed Web of Science ®Google Scholar
• HafeezSParkerCRadium-223 for the treatment of prostate cancerExpert Opin Investig Drugs201322379387
   PubMed Web of Science ®Google Scholar
• IsaacsJTThe long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancerExpert Opin Investig Drugs20101912351243
   PubMed Web of Science ®Google Scholar
• OlssonABjorkAVallon-ChristerssonJTasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumorsMol Cancer2010910720470445
   PubMed Web of Science ®Google Scholar
• StalhandskeTEriksooESandbergBA novel quinoline-3-carboxamide with interesting immunomodulatory activityInt J Immunopharmacol19824336 Available from: http://www.sciencedirect.com/science/article/pii/0192056182903125Accessed January 8, 2014
   Web of Science ®Google Scholar
• HarningRSzalayJA treatment for metastasis of murine ocular melanomaInvest Ophthalmol Vis Sci198829150515103170123
   PubMed Web of Science ®Google Scholar
• KallandTEffects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanomaCancer Res198646301830223486041
   PubMed Web of Science ®Google Scholar
• JosephIBVukanovicJIsaacsJTAntiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodentsCancer Res199656340434088758902
   PubMed Web of Science ®Google Scholar
• Hartley-AspBVukanovicJJosephIBAnti-angiogenic treatment with linomide as adjuvant to surgical castration in experimental prostate cancerJ Urol19971589029079258116
   PubMed Web of Science ®Google Scholar
• TanILLycklama a NijeholtGJPolmanCHLinomide in the treatment of multiple sclerosis: MRI results from prematurely terminated Phase-III trialsMult Scler200069910410773855
   PubMed Web of Science ®Google Scholar
• BrunmarkCRunstromAOhlssonLThe new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitisJ Neuroimmunol200213016317212225898
   PubMed Web of Science ®Google Scholar
• IsaacsJTPiliRQianDZIdentification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancerProstate2006661768177816955399
   PubMed Web of Science ®Google Scholar
• BrattOHaggmanMAhlgrenGOpen-label, clinical Phase I studies of tasquinimod in patients with castration-resistant prostate cancerBr J Cancer20091011233124019755981
   PubMed Web of Science ®Google Scholar
• PiliRHaggmanMStadlerWMPhase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancerJ Clin Oncol2011294022402821931019
   PubMed Web of Science ®Google Scholar
• DiabAMichaelLWahrenBLinomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokinesJ Neuroimmunol1998851461549630163
   PubMed Web of Science ®Google Scholar
• DalrympleSLBeckerREIsaacsJTThe quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenograftsProstate20076779079717373719
   PubMed Web of Science ®Google Scholar
• VukanovicJHartley-AspBIsaacsJTInhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancersProstate1995262352467538663
   PubMed Web of Science ®Google Scholar
• JennbackenKWelenKOlssonAInhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3- carboxamide tasquinimod (ABR-215050)Prostate20127291392422287276
   PubMed Web of Science ®Google Scholar
• WeidnerNCarrollPRFlaxJTumor angiogenesis correlates with metastasis in invasive prostate carcinomaAm J Pathol19931434014097688183
   PubMed Web of Science ®Google Scholar
• GettmanMTPacelliASlezakJRole of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinomaUrology19995447948510475358
   PubMed Web of Science ®Google Scholar
• DollJAReiherFKCrawfordSEThrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostateProstate20014929330511746276
   PubMed Web of Science ®Google Scholar
• Rodriguez-ManzanequeJCLaneTFOrtegaMAThrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factorProc Natl Acad Sci U S A200198124851249011606713
   PubMed Web of Science ®Google Scholar
• RenBYeeKOLawlerJRegulation of tumor angiogenesis by thrombospondin-1Biochim Biophys Acta2006176517818816406676
   PubMed Web of Science ®Google Scholar
• DuRLuKVPetritschCHIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasionCancer Cell20081320622018328425
   PubMed Web of Science ®Google Scholar
• LeeNVSatoMAnnisDSADAMTS1 mediates the release of antiangiogenic polypeptides from TSP1 and 2EMBO J2006255270528317082774
   PubMed Web of Science ®Google Scholar
• DvorakHFVascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapyJ Clin Oncol2002204368438012409337
   PubMed Web of Science ®Google Scholar
• Martin-MansoGGalliSRidnourLAThrombospondin 1 promotes tumor macrophage recruitment and enhances tumor cell cytotoxicity of differentiated U937 cellsCancer Res2008687090709918757424
   PubMed Web of Science ®Google Scholar
• BjorkPBjorkAVoglTIdentification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamidesPLoS Biol20097e9719402754
   PubMed Web of Science ®Google Scholar
• SinhaPOkoroCFoellDProinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cellsJ Immunol20081814666467518802069
   PubMed Web of Science ®Google Scholar
• SchmidMCVarnerJAMyeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammationJ Oncol2010201020102620490273
   PubMedGoogle Scholar
• SevkoAUmanskyVMyeloid-derived suppressor cells interact with tumors in terms of myelopoiesis, tumorigenesis and immunosuppression: thick as thievesJ Cancer2013431123386900
   PubMed Web of Science ®Google Scholar
• Ostrand-RosenbergSSinhaPMyeloid-derived suppressor cells: linking inflammation and cancerJ Immunol20091824499450619342621
   PubMed Web of Science ®Google Scholar
• YeXZYuSCBianXWContribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasisJ Genet Genomics20103742343020659706
   PubMed Web of Science ®Google Scholar
• ShenLCiesielskiMMilesKMTargeting myeloid derived suppressor cells as novel strategy to enhance immunotherapy in murine prostate cancer models. [abstract]Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research2012 Mar 31–Apr 4Chicago, IL. Philadelphia (PA): AACR
   Google Scholar
  Cancer Res2012728 Suppl Abstract nr 1551 1538-7445.AM2012-1551 Available from: http://cancerres.aacrjournals.org/cgi/content/short/72/8_MeetingAbstracts/1551
   Google Scholar
• ChengPCorzoCALuettekeNInhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 proteinJ Exp Med20082052235224918809714
   PubMed Web of Science ®Google Scholar
• ShenLCiesielskiMMilesKMModulation of suppressive myeloid populations by tasquinimod. [abstract]Proceedings of the 104th Annual Meeting of the American Association for Cancer Research2013 Apr 6–10Washington, DC. Philadelphia (PA): AACR
   Google Scholar
  Cancer Res2013738 Suppl Abstract nr 474610.1158/1538-7445.AM2013-4746 Available from: http://cancerres.aacrjournals.org/cgi/content/meeting_abstract/73/8_MeetingAbstracts/4746
   Web of Science ®Google Scholar
• TaichmanRSCooperCKellerETUse of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to boneCancer Res2002621832183711912162
   PubMed Web of Science ®Google Scholar
• ErlerJTBennewithKLCoxTRHypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic nicheCancer Cell200915354419111879
   PubMed Web of Science ®Google Scholar
• VanharaPHamplAKozubikAGrowth/differentiation factor-15: prostate cancer suppressor or promoter?Prostate Cancer Prostatic Dis20121532032822370725
   PubMed Web of Science ®Google Scholar
• HusainiYQiuMRLockwoodGPMacrophage inhibitory cytokine-1 (MIC-1/GDF15) slows cancer development but increases metastases in TRAMP prostate cancer prone micePLoS One20127e4383322952779
   PubMed Web of Science ®Google Scholar
• WhitsonRJLuciaMSLambertJRGrowth differentiation factor-15 (GDF-15) suppresses in vitro angiogenesis through a novel interaction with connective tissue growth factor (CCN2)J Cell Biochem201311461424143323280549
   PubMed Web of Science ®Google Scholar
• BeresfordAPCYP1A1: friend or foe?Drug Metab Rev1993255035178313840
   PubMed Web of Science ®Google Scholar
• NandekarPPSangamwarATCytochrome P450 1A1-mediated anticancer drug discovery: in silico findingsExpert Opin Drug Discov2012777178922716293
   PubMed Web of Science ®Google Scholar
• KeatingGMCabazitaxel: a guide to its use in hormone-refractory metastatic prostate cancerDrugs Aging201330535936523532557
   PubMed Web of Science ®Google Scholar
• HeidenreichAScholzHJRogenhoferSCabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the german compassionate-use programmeEur Urol201363697798223116658
   PubMed Web of Science ®Google Scholar
• ArmstrongAJThe CATCH prostate cancer trial: cabazitaxel and tasquinimod in men with prostate cancer Available from: http://clinicaltrials.gov/show/NCT01513733 NLM identifier: NCT01513733Accessed November 22, 2013
   Google Scholar
• DalrympleSLBeckerREZhouHTasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenograftsProstate20127263864821837778
   PubMed Web of Science ®Google Scholar
• Active Biotech ABA study of tasquinimod in men with metastatic castrate resistant prostate cancer Available from: http://clinicaltrials.gov/show/NCT01234311 NLM identifier: NCT01234311Accessed November 22, 2013
   Google Scholar
• IpsenA proof of concept study of maintenance therapy with tasquinimod in patients with metastatic castrate-resistant prostate cancer who are not progressing after a first line docetaxel based chemotherapy Available from: http://clinicaltrials.gov/show/NCT01732549 NLM identifier: NCT01732549Accessed November 22, 2013
   Google Scholar